Alzheimer’s

Biotech By Damian Garde and Adam Feuerstein

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Biotech By Adam Feuerstein and Damian Garde

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

Biotech By Adam Feuerstein

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech By Damian Garde

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

First Opinion By Dennis J. Selkoe

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

In the Lab By Sharon Begley

New prize offers $2 million for finding key to Alzheimer’s in past research

Pharma By Sharon Begley

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalot By Ed Silverman

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

Adam's Take By Adam Feuerstein

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

Alzheimer's brain illustration - Loss of connection between cells

Pharmalot By Ed Silverman

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

Biotech By Sharon Begley

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Pharmalot By Ed Silverman

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Signal Podcast By Luke Timmerman and Meg Tirrell

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions

Health By Judith Graham

Loneliness is bad for your health. This new campaign aims to curb isolation

Politics By Rebecca Robbins

Alzheimer’s is eroding his memory, but not his determination to vote

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

Gut Check By Sharon Begley

Can curcumin spice treat Alzheimer’s disease?

In the Lab By Bryan Marquard — Boston Globe

MIT’s Susan Lindquist, a pioneer in science, dies at 67

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: New bill would create review board for drug prices

Business By Damian Garde

A big Alzheimer’s drug trial now wrapping up could offer real hope — or crush it

In the Lab By Usha Lee McFarling

Most Read

Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco

Hospitalized adults need their caregivers — they aren’t visitors

Leading Alzheimer’s group splinters over claims of misplaced priorities and lavish spending

Why Nestlé — yes, that Nestlé — is acting a lot like a drug company

Gene Wilder died of Alzheimer’s. His family explains why they didn’t disclose his diagnosis

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

Dramatic decline in dementia seen among older adults in the US

Their brains had the telltale signs of Alzheimer’s. So why did they still have nimble minds?

All Coverage

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Startup Arkuda targets rapidly advancing, rare form of dementia

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

New prize offers $2 million for finding key to Alzheimer’s in past research

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions

Loneliness is bad for your health. This new campaign aims to curb isolation

Alzheimer’s is eroding his memory, but not his determination to vote

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

Can curcumin spice treat Alzheimer’s disease?

MIT’s Susan Lindquist, a pioneer in science, dies at 67

Pharmalot, Pharmalittle: New bill would create review board for drug prices

A big Alzheimer’s drug trial now wrapping up could offer real hope — or crush it

Peter Walter just won the Breakthrough Prize. His work? Trying to heal human brains